Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00271050 · ClinicalTrials.gov registry record · Phase 1
External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00271050 is a Phase 1 study that has completed, run by The Cleveland Clinic. The registered enrollment target is 12 participants.
The verdict
NCT00271050, a Phase 1 study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of the research study is to learn whether external beam radiation can be used as a safe and effective treatment for patients with bulky (≥ 5cm) sites of non-Hodgkin's lymphoma prior to treatment with 90Y-ibritumomab tiuxetan (Zevalin).
Interventions
- OTHER external beam radiotherapy plus 90-Y ibritumomab tiuxetan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2005-12 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00271050
The ClinicalTrials.gov registry entry for NCT00271050 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which external beam radiotherapy plus 90-Y ibritumomab tiuxetan is the first listed.
NCT00271050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00271050 about?
NCT00271050 is a clinical study titled "External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's Lymphoma". The purpose of the research study is to learn whether external beam radiation can be used as a safe and effective treatment for patients with bulky (≥ 5cm) sites of non-Hodgkin's lymphoma prior to treatment with 90Y-ibritumomab tiuxetan (Zevalin).
What is the current status of trial NCT00271050?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2005-12. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00271050?
The interventions under investigation include: external beam radiotherapy plus 90-Y ibritumomab tiuxetan (OTHER).
Who is sponsoring clinical trial NCT00271050?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.